This medicine is authorised for use in the European Union.


Ogluo is a medicine for treating severe hypoglycaemia (very low levels of glucose in the blood) in patients with diabetes who are at least 2 years old.

Hypoglycaemia can occur when diabetes medicines to reduce blood glucose cause glucose levels to fall too low. In severe cases, patients can faint or become unconscious and they must be treated urgently to raise glucose levels.

Ogluo contains the active substance glucagon.

Ogluo is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance. However, Ogluo is available as a solution for injection while the reference medicine is available as a powder that needs to be dissolved to make up the injection. The reference medicine for Ogluo is GlucaGen.

This EPAR was last updated on 26/02/2021

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Xeris Pharmaceuticals Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

8th floor block east
Iveagh Court
Harcourt Road
Dublin 2

Product information

11/02/2021 Ogluo - EMEA/H/C/005391 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Pancreatic hormones

  • Glycogenolytic hormones

Therapeutic indication

Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Assessment history

How useful was this page?

Add your rating